Zinc finger transcription factors designed for bispecific coregulation of ErbB2 and ErbB3 receptors: Insights into ErbB receptor biology

Molecular and Cellular Biology

Volumn 25, Issue 20, 2005, Pages 9082-9091

  Lund, Caren V ^a   Popkov, Mikhail ^a   Magnenat, Laurent ^a   Barbas III, Carlos F ^a  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COLLAGEN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR 3; INTERCELLULAR ADHESION MOLECULE 1; LAMININ; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATIDYLINOSITOL 3 KINASE; TRANSCRIPTION FACTOR; TYROSINE KINASE RECEPTOR; ZINC FINGER PROTEIN;

ARTICLE; CANCER CELL CULTURE; CELL DIFFERENTIATION; CELL GROWTH; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; DOWN REGULATION; GENE CONTROL; GENE OVEREXPRESSION; GENE THERAPY; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; SIGNAL TRANSDUCTION; SQUAMOUS CELL CARCINOMA;

AMINO ACID SEQUENCE; BINDING SITES; CELL DIFFERENTIATION; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; DRUG DESIGN; GENE EXPRESSION REGULATION; HUMANS; MAP KINASE SIGNALING SYSTEM; MOLECULAR SEQUENCE DATA; PROTEIN ENGINEERING; RECEPTOR, ERBB-2; RECEPTOR, ERBB-3; SIGNAL TRANSDUCTION; TRANSCRIPTION FACTORS; ZINC FINGERS;

EID: 26444464763     PISSN: 02707306     EISSN: None     Source Type: Journal    
DOI: 10.1128/MCB.25.20.9082-9091.2005     Document Type: Article

References (84)

1. Adelsman, M. A., J. B. McCarthy, and Y. Shimizu. 1999. Stimulation of beta1-integrin function by epidermal growth factor and heregulin-beta has distinct requirements for erbB2 but a similar dependence on phosphoinositide 3-OH kinase. Mol. Biol. Cell 10:2861-2878.
2. Aigner, A., H. Juhl, C. Malerczyk, A. Tkybusch, C. C. Benz, and F. Czubayko. 2001. Expression of a truncated 100 kDa HER2 splice variant acts as an endogenous inhibitor of tumour cell proliferation. Oncogene 20:2101-2111.
3. Albanell, J., J. Codony, A. Rovira, B. Mellado, and P. Gascon. 2003. Mechanism of action of anti-HER2 monoclonal antibodies: scientific update on trastuzumab and 2C4. Adv. Exp. Med. Biol. 532:253-268.
4. Baeckstrom, D., P. J. Lu, and J. Taylor-Papadimitriou. 2000. Activation of the alpha2beta1 integrin prevents c-erbB2-induced scattering and apoptosis of human mammary epithelial cells in collagen. Oncogene 19:4592-4603.
5. Barbacci, E. G., L. R. Puslilnik, A. M. Rossi, E. Emerson, P. E. Miller, B. P. Boscoe, E. D. Cox, K. K. Iwata, J. P. Jani, K. Provoncha, J. C. Kath, Z. Liu, and J. D. Moyer. 2003. The biological and biochemical effects of CP-654577, a selective erbB2 kinase inhibitor, on human breast cancer cells. Cancer Res. 63:4450-4459.
6. Baulida, J., M. H. Kraus, M. Alimandi, P. P. Di Fiore, and G. Carpenter. 1996. All ErbB receptors other than the epidermal growth factor receptor are endocytosis impaired. J. Biol. Chem. 271:5251-5257.
7. Beerli, R. R., and C. F. Barbas III. 2002. Engineering polydactyl zinc-finger transcription factors. Nat. Biotechnol. 20:135-141.
8. Beerli, R. R., B. Dreier, and C. F. Barbas III. 2000. Positive and negative regulation of endogenous genes by designed transcription factors. Proc. Natl. Acad. Sci. USA 97:1495-1500.
9. Beerli, R. R., D. J. Segal, B. Dreier, and C. F. Barbas III. 1998. Toward controlling gene expression at will: specific regulation of the erbB-2/HER-2 promoter by using polydactyl zinc finger proteins constructed from modular building blocks. Proc. Natl. Acad. Sci. USA 95:14628-14633.
10. Blancafort, P., D. J. Segal, and C. F. Barbas III. 2004. Designing transcription factor architectures for drug discovery. Mol. Pharmacol. 66:1361-1371.
11. Blume-Jensen, P., and T. Hunter. 2001. Oncogenic kinase signalling. Nature 411:355-365.
12. Cabodi, S., L. Moro, E. Bergatto, E. Boeri Erba, P. Di Stefano, E. Turco, G. Tarone, and P. Defilippi. 2004. Integrin regulation of epidermal growth factor (EGF) receptor and of EGF-dependent responses. Biochem. Soc. Trans. 32:438-442.
13. Campbell, T. N., and F. Y. Choy. 2005. RNA interference: past, present and future. Curr. Issues Mol. Biol. 7:1-6.
14. Caponigro, F., R. Formato, M. Caraglia, N. Normanno, and R. V. Iaffaioli. 2005. Monoclonal antibodies targeting epidermal growth factor receptor and vascular endothelial growth factor with a focus on head and neck tumors. Curr. Opin. Oncol. 17:212-217.
15. Casalini, P., M. V. Iorio, E. Galmozzi, and S. Menard. 2004. Role of HER receptors family in development and differentiation. J. Cell. Physiol: 200:343-350.
16. Chausovsky, A., H. Waterman, M. Elbaum, Y. Yarden, B. Geiger, and A. D. Bershadsky. 2000. Molecular requirements for the effect of neuregulin on cell spreading, motility and colony organization. Oncogene 19:878-888.
17. Chen, C. H., G. A. Chernis, V. Q. Hoang, and R. Landgraf. 2003. Inhibition of heregulin signaling by an aptamer that preferentially binds to the oligomeric form of human epidermal growth factor receptor-3. Proc. Natl. Acad. Sci. USA 100:9226-9231.
18. Chiang, S. Y., R. W. Burli, C. C. Benz, L. Gawron, G. K. Scott, P. B. Dervan, and T. A. Beerman. 2000. Targeting the ets binding site of the HER2/neu promoter with pyrrole-imidazole polyamides. J. Biol. Chem. 275:24246-24254.
19. Chu, I., K. Blackwell, S. Chen, and J. Slingerland. 2005. The dual ErbB1/ErbB2 inhibitor, lapatinib (GW572016), cooperates with tamoxifen to inhibit both cell proliferation- and estrogen-dependent gene expression in antiestrogen-resistant breast cancer. Cancer Res. 65:18-25.
20. D'Souza, B., F. Berdichevsky, N. Kyprianou, and J. Taylor-Papadimitriou. 1993. Collagen-induced morphogenesis and expression of the alpha 2-integrin subunit is inhibited in c-erbB2-transfected human mammary epithelial cells. Oncogene 8:1797-1806.
21. Eicheler, W., D. Zips, A. Dorfler, R. Grenman, and M. Baumann. 2002. Splicing mutations in TP53 in human squamous cell carcinoma lines influence immunohistochemical detection. J. Histochem. Cytochem. 50:197-204.
22. Falcioni, R., A. Antonini, P. Nistico, S. Di Stefano, M. Crescenzi, P. G. Natali, and A. Sacchi. 1997. Alpha 6 beta 4 and alpha 6 beta 1 integrins associate with ErbB-2 in human carcinoma cell lines. Exp. Cell Res. 236:76-85.
23. Fedi, P., J. H. Pierce, P. P. di Fiore, and M. H. Kraus. 1994. Efficient coupling with phosphatidylinositol 3-kinase, but not phospholipase C gamma or GTPase-activating protein, distinguishes ErbB-3 signaling from that of other ErbB/EGFR family members. Mol. Cell. Biol. 14:492-500.
24. Giard, D. J., S. A. Aaronson, G. J. Todaro, P. Arnstein, J. H. Kersey, H. Dosik, and W. P. Parks. 1973. In vitro cultivation of human tumors: establishment of cell lines derived from a series of solid tumors. J. Natl. Cancer Inst. 51:1417-1423.
25. Graus-Porta, D., R. R. Beerli, J. M. Daly, and N. E. Hynes. 1997. ErbB-2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling. EMBO J. 16:1647-1655.
26. Graus-Porta, D., R. R. Beerli, and N. E. Hynes. 1995. Single-chain antibody-mediated intracellular retention of ErbB-2 impairs Neu differentiation factor and epidermal growth factor signaling. Mol. Cell. Biol. 15:1182-1191.
27. Gross, M. E., R. L. Shazer, and D. B. Agus. 2004. Targeting the HER-kinase axis in cancer. Semin. Oncol. 31:9-20.
28. Hansen, L. A., R. L. Woodson II, S. Holbus, K. Strain, Y. C. Lo, and S. H. Yuspa. 2000. The epidermal growth factor receptor is required to maintain the proliferative population in the basal compartment of epidermal tumors. Cancer Res. 60:3328-3332.
29. Harari, D., and Y. Yarden. 2000. Molecular mechanisms underlying ErbB2/HER2 action in breast cancer. Oncogene 19:6102-6114.
30. Hijazi, M. M., E. W. Thompson, C. Tang, P. Coopman, J. A. Torri, D. Yang, S. C. Mueller, and R. Lupu. 2000. Heregulin regulates the actin cytoskeleton and promotes invasive properties in breast cancer cell lines. Int. J. Oncol. 17:629-641.
31. Hintermann, E., M. Bilban, A. Sharabi, and V. Quaranta. 2001. Inhibitory role of alpha 6 beta 4-associated erbB-2 and phosphoinositide 3-kinase in keratinocyte haptotactic migration dependent on alpha 3 beta 1 integrin. J. Cell Biol. 153:465-478.
32. Hintermann, E., and V. Quaranta. 2004. Epithelial cell motility on laminin-5: regulation by matrix assembly, proteolysis, integrins and erbB receptors. Matrix Biol. 23:75-85.
33. Holbro, T., R. R. Beerli, F. Maurer, M. Koziczak, C. F. Barbas III, and N. E. Hynes. 2003. The ErbB2/ErbB3 heterodimer functions as an oncogenic unit: ErbB2 requires ErbB3 to drive breast tumor cell proliferation. Proc. Natl. Acad. Sci. USA 100:8933-8938.
34. Holbro, T., and N. E. Hynes. 2004. ErbB receptors: directing key signaling networks throughout life. Annu. Rev. Pharmacol. Toxicol. 44:195-217.
35. Hudelist, G., C. F. Singer, M. Manavi, K. Pischinger, E. Kubista, and K. Czerwenka. 2003. Co-expression of ErbB-family members in human breast cancer: Her-2/neu is the preferred dimerization candidate in nodal-positive tumors. Breast Cancer Res. Treat. 80:353-361.
36. Jones, J. T., R. W. Akita, and M. X. Sliwkowski. 1999. Binding specificities and affinities of egf domains for ErbB receptors. FEBS Lett. 447:227-231.
37. Kalnina, Z., P. Zayakin, K. Silina, and A. Line. 2005. Alterations of pre-mRNA splicing in cancer. Genes Chromosomes Cancer 42:342-357.
38. Kawahara, E., N. Nakada, T. Hikichi, J. Kobayashi, and I. Nakanishi. 2002. EGF and beta1 integrin convergently regulate migration of A431 carcinoma cell through MAP kinase activation. Exp. Cell Res. 272:84-91.
39. Kim, V. N. 2003. RNA interference in functional genomics and medicine. J. Korean Med. Sci. 18:309-318.
40. Klos, K. S., X. Zhou, S. Lee, L. Zhang, W. Yang, Y. Nagata, and D. Yu. 2003. Combined trastuzumab and paclitaxel treatment better inhibits ErbB-2-mediated angiogenesis in breast carcinoma through a more effective inhibition of Akt than either treatment alone. Cancer 98:1377-1385.
41. Kraus, M. H., W. Issing, T. Miki, N. C. Popescu, and S. A. Aaronson. 1989. Isolation and characterization of ERBB3, a third member of the ERBB/ epidermal growth factor receptor family: evidence for overexpression in a subset of human mammary tumors. Proc. Natl. Acad. Sci. USA 86:9193-9197.
42. Lee, J. W., and R. Juliano. 2004. Mitogenic signal transduction by integrin- and growth factor receptor-mediated pathways. Mol. Cell 17:188-202.
43. 1 integrin function. Mol. Biol. Cell 13:2894-2908.
44. Lorens, J. B., C. Sousa, M. K. Bennett, S. M. Molineaux, and D. G. Payan. 2001. The use of retroviruses as pharmaceutical tools for target discovery and validation in the field of functional genomics. Curr. Opin. Biotechnol. 12:613-621.
45. Lund, C. V., P. Blancafort, M. Popkov, and C. F. Barbas III. 2004. Promoter-targeted phage display selections with preassembled synthetic zinc finger libraries for endogenous gene regulation. J. Mol. Biol. 340:599-613.
46. Magnenat, L., P. Blancafort, and C. F. Barbas III. 2004. In vivo selection of combinatorial libraries and designed affinity maturation of polydactyl zinc finger transcription factors for ICAM-1 provides new insights into gene regulation. J. Mol. Biol. 341:635-649.
47. Margolin, J. F., J. R. Friedman, W. K. Meyer, H. Vissing, H. J. Thiesen, and F. J. Rauscher III. 1994. Kruppel-associated boxes are potent transcriptional repression domains. Proc. Natl. Acad. Sci. USA 91:4509-4513.
48. Marone, R., D. Hess, D. Dankort, W. J. Muller, N. E. Hynes, and A. Badache. 2004. Memo mediates ErbB2-driven cell motility. Nat. Cell Biol. 6:515-522.
49. Nagy, P., D. J. Arndt-Jovin, and T. M. Jovin. 2003. Small interfering RNAs suppress the expression of endogenous and GFP-fused epidermal growth factor receptor (erbB 1) and induce apoptosis in erbB1-overexpressing cells. Exp. Cell Res. 285:39-49.
50. Nicholson, K. M., and N. G. Anderson. 2002. The protein kinase B/Akt signalling pathway in human malignancy. Cell. Signal. 14:381-395.
51. Olayioye, M. A. 2001. Update on HER-2 as a target for cancer therapy: intracellular signaling pathways of ErbB2/HER-2 and family members. Breast Cancer Res. 3:385-389.
52. Olayioye, M. A., D. Graus-Porta, R. R. Beerli, J. Rohrer, B. Gay, and N. E. Hynes. 1998. ErbB-1 and ErbB-2 acquire distinct signaling properties dependent upon their dimerization partner. Mol. Cell. Biol. 18:5042-5051.
53. Olayioye, M. A., R. M. Neve, H. A. Lane, and N. E. Hynes. 2000. The ErbB signaling network: receptor heterodimerization in development and cancer. EMBO J. 19:3159-3167.
54. O'Toole, E. A. 2001. Extracellular matrix and keratinocyte migration. Clin. Exp. Dermatol. 26:525-530.
55. Penington, D. J., I. Bryant, and D. J. Riese II. 2002. Constitutively active ErbB4 and ErbB2 mutants exhibit distinct biological activities. Cell Growth Differ. 13:247-256.
56. Plowman, G. D., J. M. Culouscou, G. S. Whitney, J. M. Green, G. W. Carlton, L. Foy, M. G. Neubauer, and M. Shoyab. 1993. Ligand-specific activation of HER4/p180erbB4, a fourth member of the epidermal growth factor receptor family. Proc. Natl. Acad. Sci. USA 90:1746-1750.
57. Rabindran, S. K., C. M. Discafani, E. C. Rosfjord, M. Baxter, M. B. Floyd, J. Golas, W. A. Hallett, B. D. Johnson, R. Nilakantan, E. Overbeek, M. F. Reich, R. Shen, X. Shi, H. R. Tsou, Y. F. Wang, and A. Wissner. 2004. Antitumor activity of HK1-272, an orally active, irreversible inhibitor of the HER-2 tyrosine kinase. Cancer Res. 64:3958-3965.
58. Roux, P. P., and J. Blenis. 2004. ERK and p38 MAPK-activated protein kinases: a family of protein kinases with diverse biological functions. Microbiol. Mol. Biol. Rev. 68:320-344.
59. Salomon, D. S., R. Brandt, F. Ciardiello, and N. Normanno. 1995. Epidermal growth factor-related peptides and their receptors in human malignancies. Crit. Rev. Oncol. Hematol. 19:183-232.
60. Schechter, A. L., D. F. Stern, L. Vaidyanathan, S. J. Decker, J. A. Drebin, M.I. Greene, and R.A. Weinberg. 1984. The neu oncogene: an erb-B-related gene encoding a 185,000-Mr tumour antigen. Nature 312:513-516.
61. Schlessinger, J. 2000. Cell signaling by receptor tyrosine kinases. Cell 103:211-225.
62. Scott, G. K., R. Robles, J. W. Park, P. A. Montgomery, J. Daniel, W. E. Holmes, J. Lee, G. A. Keller, W. L. Li, B. M. Fendly, et al. 1993. A truncated intracellular HER2/neu receptor produced by alternative RNA processing affects growth of human carcinoma cells. Mol. Cell. Biol. 13:2247-2257.
63. Sibilia, M., A. Fleischmann, A. Behrens, L. Stingl, J. Carroll, F. M. Watt, J. Schlessinger, and E. F. Wagner. 2000. The EGF receptor provides an essential survival signal for SOS-dependent skin tumor development. Cell 102:211-220.
64. Slamon, D. J., G. M. Clark, S. G. Wong, W. J. Levin, A. Ullrich, and W. L. McGuire. 1987. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235:177-182.
65. Spencer, K. S., D. Graus-Porta, J. Leng, N. E. Hynes, and R. L. Klemke. 2000. ErbB2 is necessary for induction of carcinoma cell invasion by ErbB family receptor tyrosine kinases. J. Cell Biol. 148:385-397.
66. Staalesen, V., J. Falck, S. Geisler, J. Bartkova, A. L. Borresen-Dale, J. Lukas, J. R. Lillehaug, J. Bartek, and P. E. Lonning. 2004. Alternative splicing and mutation status of CHEK2 in stage III breast cancer. Oncogene 23:8535-8544.
67. Sternberg, L. R., J. C. Byrd, G. C. Hansson, K. F. Liu, and R. S. Bresalier. 2004. Alternative splicing of the human MUC2 gene. Arch. Biochem. Biophys. 421:21-33.
68. Stoll, S. W., S. Kansra, S. Peshick, D. W. Fry, W. R. Leopold, J. F. Wiesen, M. Sibilia, T. Zhang, Z. Werb, R. Derynck, E. F. Wagner, and J. T. Elder. 2001. Differential utilization and localization of ErbB receptor tyrosine kinases in skin compared to normal and malignant keratinocytes. Neoplasia 3:339-350.
69. Sudbo, J., and A. Reith. 2005. The evolution of predictive oncology and molecular-based therapy for oral cancer prevention. Int. J. Cancer 115:339-345.
70. Suzuki, T., B. Anderegg, T. Ohkawa, A. Irie, O. Engebraaten, M. Halks-Miller, P. S. Holm, D. T. Curiel, M. Kashani-Sabet, and K. J. Scanlon. 2000. Adenovirus-mediated ribozyme targeting of HER-2/neu inhibits in vivo growth of breast cancer cells. Gene Ther. 7:241-248.
71. Sweeney, C., and K. L. Carraway III. 2000. Ligand discrimination by ErbB receptors: differential signaling through differential phosphorylation site usage. Oncogene 19:5568-5573.
72. Sweeney, C., D. Fambrough, C. Huard, A. J. Diamonti, E. S. Lander, L. C. Cantley, and K. L. Carraway III. 2001. Growth factor-specific signaling pathway stimulation and gene expression mediated by ErbB receptors. J. Biol. Chem. 276:22685-22698.
73. Thor, A. D., S. Liu, S. Edgerton, D. Moore II, K. M. Kasowitz, C. C. Benz, D. F. Stern, and M. P. DiGiovanna. 2000. Activation (tyrosine phosphorylation) of ErbB-2 (HER-2/neu): a study of incidence and correlation with outcome in breast cancer. J. Clin. Oncol. 18:3230-3239.
74. Tovey, S. M., C. J. Witton, J. M. Bartlett, P. D. Stanton, J. R. Reeves, and T. G. Cooke. 2004. Outcome and human epidermal growth factor receptor (HER) 1-4 status in invasive breast carcinomas with proliferation indices evaluated by bromodeoxyuridine labelling. Breast Cancer Res. 6:R246-R251.
75. Tsai, M. S., L. A. Shamon-Taylor, I. Mehmi, C. K. Tang, and R. Lupu. 2003. Blockage of heregulin expression inhibits tumorigenicity and metastasis of breast cancer. Oncogene 22:761-768.
76. Tsang, D. K., and D. L. Crowe. 1999. The mitogen activated protein kinase pathway is required for proliferation but not invasion of human squamous cell carcinoma lines. Int. J. Oncol. 15:519-523.
77. Ullrich, A., L. Coussens, J. S. Hayflick, T. J. Dull, A. Gray, A. W. Tam, J. Lee, Y. Yarden, T. A. Libermann, J. Schlessinger, et al. 1984. Human epidermal growth factor receptor cDNA sequence and aberrant expression of the amplified gene in A431 epidermoid carcinoma cells. Nature 309:418-425.
78. van der Horst, E. H., M. Murgia, M. Treder, and A. Ullrich. 2005. Anti-HER-3 MAbs inhibit HER-3-mediated signaling in breast cancer cell lines resistant to anti-HER-2 antibodies. Int. J. Cancer 115:519-527.
79. Vijapurkar, U., M. S. Kim, and J. G. Koland. 2003. Roles of mitogen-activated protein kinase and phosphoinositide 3′-kinase in ErbB2/ErbB3 coreceptor-mediated heregulin signaling. Exp. Cell Res. 284:291-302.
80. Walker, F., A. Kato, L. J. Gonez, M. L. Hibbs, N. Pouliot, A. Levitzki, and A. W. Burgess. 1998. Activation of the Ras/mitogen-activated protein kinase pathway by kinase-defective epidermal growth factor receptors results in cell survival but not proliferation. Mol. Cell. Biol. 18:7192-7204.
81. Wiley, H. S. 2003. Trafficking of the ErbB receptors and its influence on signaling. Exp. Cell Res. 284:78-88.
82. Xia, W., L. H. Liu, P. Ho, and N. L. Spector. 2004. Truncated ErbB2 receptor (p95ErbB2) is regulated by heregulin through heterodimer formation with ErbB3 yet remains sensitive to the dual EGFR/ErbB2 kinase inhibitor GW572016. Oncogene 23:646-653.
83. Yang, G., K. Q. Cai, J. A. Thompson-Lanza, R. C. Bast, Jr., and J. Liu. 2004. Inhibition of breast and ovarian tumor growth through multiple signaling pathways by using retrovirus-mediated small interfering RNA against Her-2/neu gene expression. J. Biol. Chem. 279:4339-4345.
84. Yarden, Y., and M. X. Sliwkowski. 2001. Untangling the ErbB signalling network. Nat. Rev. Mol. Cell Biol. 2:127-137.